Literature DB >> 23442571

Emergence of anxiety-like behaviours in depressive-like Cpe(fat/fat) mice.

Ramona M Rodriguiz1, John J Wilkins, Thomas K Creson, Reeta Biswas, Iryna Berezniuk, Arun D Fricker, Lloyd D Fricker, William C Wetsel.   

Abstract

Cpe(fat/fat) mice have a point mutation in carboxypeptidase E (Cpe), an exopeptidase that removes C-terminal basic amino acids from intermediates to produce bioactive peptides. The mutation renders the enzyme inactive and unstable. The absence of Cpe activity in these mutants leads to abnormal processing of many peptides, with elevated levels of intermediates and greatly reduced levels of the mature peptides. Cpe(fat/fat) mice develop obesity, diabetes and infertility in adulthood. We examined whether anxiety- and/or depressive-like behaviours are also present. Anxiety-like responses are not evident in young Cpe(fat/fat) mice (∼60 d), but appear in older animals (>90 d). These behaviours are reversed by acute treatment with diazepam or fluoxetine. In contrast, increased immobilities in forced swim and tail suspension are evident in all age groups examined. These behaviours are reversed by acute administration of reboxetine. In comparison acute treatments with fluoxetine or bupropion are ineffective; however, immobility times are normalized with 2 wk treatment. These data demonstrate that Cpe(fat/fat) mice display depressive-like responses aged ∼60 d, whereas anxiety-like behaviours emerge ∼1 month later. In tail suspension, the reboxetine findings show that noradrenergic actions of antidepressants are intact in Cpe(fat/fat) mice. The ability of acute fluoxetine treatment to rescue anxiety-like while leaving depressive-like responses unaffected suggests that serotonin mechanisms underlying these behaviours are different. Since depressive-like responses in the Cpe(fat/fat) mice are rescued by 2 wk, but not acute, treatment with fluoxetine or bupropion, these mice may serve as a useful model that resembles human depression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23442571      PMCID: PMC3881283          DOI: 10.1017/S1461145713000059

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  45 in total

Review 1.  Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides.

Authors:  N G Seidah; M Chrétien
Journal:  Brain Res       Date:  1999-11-27       Impact factor: 3.252

2.  Anxiety, depression, hunger and body composition: III. Their relationships in obese patients.

Authors:  P Cugini; M Cilli; A Salandri; P Ceccotti; A Di Marzo; A Rodio; S Fontana; A M Pellegrino; G P De Francesco; S Coda; F De Vito; L Colosi; C M Petrangeli; C Giovannini
Journal:  Eat Weight Disord       Date:  1999-09       Impact factor: 4.652

Review 3.  Peptides, enzymes and obesity: new insights from a 'dead' enzyme.

Authors:  L D Fricker; E H Leiter
Journal:  Trends Biochem Sci       Date:  1999-10       Impact factor: 13.807

Review 4.  Cocaine- and amphetamine related transcript (CART) and anxiety.

Authors:  Lisa M Stanek
Journal:  Peptides       Date:  2006-06-13       Impact factor: 3.750

5.  Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior.

Authors:  Zhe-Yu Chen; Deqiang Jing; Kevin G Bath; Alessandro Ieraci; Tanvir Khan; Chia-Jen Siao; Daniel G Herrera; Miklos Toth; Chingwen Yang; Bruce S McEwen; Barbara L Hempstead; Francis S Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

6.  Behavioral characterization of neuropeptide Y knockout mice.

Authors:  A W Bannon; J Seda; M Carmouche; J M Francis; M H Norman; B Karbon; M L McCaleb
Journal:  Brain Res       Date:  2000-06-16       Impact factor: 3.252

7.  Major depressive disorder and axis I diagnostic comorbidity.

Authors:  Mark Zimmerman; Iwona Chelminski; Wilson McDermut
Journal:  J Clin Psychiatry       Date:  2002-03       Impact factor: 4.384

8.  Effects of chronic and acute stressors and CRF on depression-like behavior in mice.

Authors:  Artur H Swiergiel; Igor L Leskov; Adrian J Dunn
Journal:  Behav Brain Res       Date:  2007-07-20       Impact factor: 3.332

9.  Obesity and mental disorders in the adult general population.

Authors:  Kate M Scott; Magnus A McGee; J Elisabeth Wells; Mark A Oakley Browne
Journal:  J Psychosom Res       Date:  2008-01       Impact factor: 3.006

10.  Human urocortin II: mild locomotor suppressive and delayed anxiolytic-like effects of a novel corticotropin-releasing factor related peptide.

Authors:  Glenn R Valdez; Koki Inoue; George F Koob; Jean Rivier; Wylie Vale; Eric P Zorrilla
Journal:  Brain Res       Date:  2002-07-05       Impact factor: 3.252

View more
  13 in total

1.  Probing the Allosteric Role of the α5 Subunit of α3β4α5 Nicotinic Acetylcholine Receptors by Functionally Selective Modulators and Ligands.

Authors:  Caroline Ray; Erik J Soderblom; Yushi Bai; F Ivy Carroll; Marc G Caron; Larry S Barak
Journal:  ACS Chem Biol       Date:  2017-01-24       Impact factor: 5.100

2.  Cortical Neuron Migration and Dendrite Morphology are Regulated by Carboxypeptidase E.

Authors:  Chen Liang; Damien Carrel; Anton Omelchenko; Hyuck Kim; Aashini Patel; Isabelle Fanget; Bonnie L Firestein
Journal:  Cereb Cortex       Date:  2019-07-05       Impact factor: 5.357

3.  Mice lacking proSAAS display alterations in emotion, consummatory behavior and circadian entrainment.

Authors:  Dipendra K Aryal; Ramona M Rodriguiz; Ngoc Lien Nguyen; Matthew W Pease; Daniel J Morgan; John Pintar; Lloyd D Fricker; William C Wetsel
Journal:  Genes Brain Behav       Date:  2022-07-25       Impact factor: 3.708

Review 4.  Carboxypeptidases in disease: insights from peptidomic studies.

Authors:  Matthew R Sapio; Lloyd D Fricker
Journal:  Proteomics Clin Appl       Date:  2014-03-24       Impact factor: 3.494

Review 5.  Carboxypeptidase E (NF-α1): a new trophic factor in neuroprotection.

Authors:  Yong Cheng; Niamh X Cawley; Y Peng Loh
Journal:  Neurosci Bull       Date:  2014-04-01       Impact factor: 5.203

6.  Neurotrophic factor-α1 prevents stress-induced depression through enhancement of neurogenesis and is activated by rosiglitazone.

Authors:  Y Cheng; R M Rodriguiz; S R K Murthy; V Senatorov; E Thouennon; N X Cawley; D K Aryal; S Ahn; B Lecka-Czernik; W C Wetsel; Y P Loh
Journal:  Mol Psychiatry       Date:  2014-10-21       Impact factor: 15.992

7.  Truncating Homozygous Mutation of Carboxypeptidase E (CPE) in a Morbidly Obese Female with Type 2 Diabetes Mellitus, Intellectual Disability and Hypogonadotrophic Hypogonadism.

Authors:  Suzanne I M Alsters; Anthony P Goldstone; Jessica L Buxton; Anna Zekavati; Alona Sosinsky; Andrianos M Yiorkas; Susan Holder; Robert E Klaber; Nicola Bridges; Mieke M van Haelst; Carel W le Roux; Andrew J Walley; Robin G Walters; Michael Mueller; Alexandra I F Blakemore
Journal:  PLoS One       Date:  2015-06-29       Impact factor: 3.240

8.  Neuropeptidomic Analysis of a Genetically Defined Cell Type in Mouse Brain and Pituitary.

Authors:  Lloyd D Fricker; Alexandre K Tashima; Amanda K Fakira; Ute Hochgeschwender; William C Wetsel; Lakshmi A Devi
Journal:  Cell Chem Biol       Date:  2020-11-19       Impact factor: 8.116

9.  Carboxypeptidase E Regulates Activity-Dependent TrkB Neuronal Surface Insertion and Hippocampal Memory.

Authors:  Na Li; Shuai-Wen Teng; Ling Zhao; Jing-Rui Li; Jia-Ling Xu; Na Li; Jia-Cheng Shuai; Zhe-Yu Chen
Journal:  J Neurosci       Date:  2021-07-15       Impact factor: 6.167

10.  The expression of hepatic carboxypeptidase E is decreased in patients with cholesterol gallstone.

Authors:  Shu-Long Dai; Jin Zhou; Kun-Xing Yang; Shi-Yong Yang
Journal:  Saudi J Gastroenterol       Date:  2015 Jul-Aug       Impact factor: 2.485

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.